InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline

InMed Pharmaceuticals Inc.

Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.
Estimated severance costs of ~$550K and other expenses ~$120K; partially offset by product sale profits during wind-down.
Company will focus exclusively on INM-901 (Alzheimer's) and INM-089 (dry AMD) drug candidates; commercial revenue stream eliminated.
Pro forma financial statements treat BayMedica as discontinued operations; revenue from commercial ops reduced to $0.

item 2.05item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.